Clinical Trial Update: A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating valbenazine for tardive dyskinesia in adults who remain symptomatic on or after VMAT2 inhibitor treatment; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tardive Dyskinesia

Drugs mentioned

• Valbenazine (valbenazine)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: RECRUITING